Marion Koopmans, right, and Peter Ben Embarek, center, of the World Health Organization team say farewell to their Chinese counterpart Liang Wannian, left, after a WHO-China Joint Study Press Conference held at the end of the WHO mission in Wuhan, China, Tuesday, Feb. 9, 2021. (AP Photo/Ng Han Guan)
By Emily Wang Fujiyama
The coronavirus most likely first appeared in humans after jumping from an animal, a team of international and Chinese scientists looking for the origins of COVID-19 said Tuesday, dismissing as unlikely an alternate theory that the virus leaked from a Chinese lab.
A closely watched visit by World Health Organization experts to Wuhan — the Chinese city where the first coronavirus cases were discovered — did not dramatically change the current understanding of the early days of the pandemic, said Peter Ben Embarek, the leader of the WHO mission.
But it did “add details to that story,” he said at a news conference as the group wrapped up a nearly four-week visit to the city.
And it allowed the joint Chinese-WHO team to rule out one theory on the origins of the virus. The Wuhan Institute of Virology has collected many virus samples, leading to allegations that it may have been the source of the original outbreak, whether on purpose or accidentally.
But experts now consider the possibility of such a leak so improbable that it will not be suggested as an avenue of future study, said Embarek, a WHO food safety and animal diseases expert.
China had already strongly rejected that possibility and has promoted other theories. The Chinese and foreign experts considered several ideas for how the disease first ended up in humans, leading to a pandemic that has now killed more than 2.3 million people worldwide.
Embarek said the initial findings suggest the most likely pathway the virus followed was from a bat to another animal and then to humans, adding that would require further research.
“The findings suggest that the laboratory incidents hypothesis is extremely unlikely to explain the introduction of the virus to the human population," he said.
The mission was intended to be an initial step in the process of understanding the origins of the virus, which scientists have posited may have passed to humans through a wild animal, such as a pangolin or bamboo rat. Transmission directly from bats to humans or through the trade in frozen food products are also possibilities, Embarek said.
The WHO team's visit is politically sensitive for Beijing, which is concerned about being blamed for alleged missteps in its early response to the outbreak. An AP investigation has found that the Chinese government put limits on research into the outbreak and ordered scientists not to speak to reporters.
The team — which includes experts from 10 countries who arrived on Jan. 14 — visited the Huanan Seafood Market, the site of an early cluster of cases in late 2019.
Marion Koopmans, a Dutch virologist on the team, said that some animals at the market were susceptible or suspected to be susceptible to the virus, including rabbits and bamboo rats. And some could be traced to farms or traders in regions that are home to the bats that carry the closest related virus to the one that causes COVID-19.
She said the next step would be to look more closely at farms.
Liang Wannian, the head of the Chinese side, said the virus also appeared to have been spreading in other parts of the city than the market, so it remains possible that the virus originated elsewhere.
The team found no evidence that the disease was spreading widely any earlier than the initial outbreak in the second half of December 2019.
“We haven’t been able to fully do the research, but there is no indication there were clusters before what we saw happen in the later part of December in Wuhan,” Liang said.
Another member of the WHO team, British-born zoologist Peter Daszak, told The Associated Press late last week that they enjoyed a greater level of openness than they had anticipated, and that they were granted full access to all sites and personnel they requested.
The visit by the WHO team took months to negotiate. China only agreed to it amid international pressure at the WHO's World Health Assembly meeting last May, and Beijing has continued to resist calls for a strictly independent investigation.
While China has weathered some localized resurgences of infection since getting the outbreak under control last year, life in Wuhan itself has largely returned to normal.
___
Associated Press writer Ken Moritsugu in Beijing contributed to this report.
The FDA has granted emergency use authorization to Pfizer's pill to treat covid-19. The treatment, called Paxlovid, is the first antiviral covid-19 pill that people can take at home.
Pfizer says the pill can reduce the risk of severe illness by 90 percent and is intended for people at high risk for severe disease, including those over 65, people with obesity, diabetes, or a weakened immune system. Professor Peter Pitts, Founder, Center for Medicine in the Public Interest & Former FDA Associate joined Wake Up with Cheddar to discuss.
Ahead of a four day week for the markets due to the upcoming Christmas holiday, investors hoping for a quiet end to the year, or even a Santa Claus rally, may not be in luck. Investors are still digesting the latest from the Fed regarding a quicker than expected taper, as well as ever increasing blow back as the Omicron variant spreads. Octavio Marenzi, CEO of Opimas LLC, explains why the markets have been so volatile ever since the emergence of the latest variant and what to expect going forward into 2022.
Carlo and Baker cover the heartening news on the Covid front ahead of the holiday, plus President Biden punting student loan repayments again, a new space telescope and Love, Hate, Ate: Christmas Eve Eve Edition!
Pfizer, one of the makers of a currently available COVID-19 vaccine, has taken another critical step forward in combatting the pandemic by getting regulatory approval for Paxlovid, a pill treatment rather than IV or injection as others have been. Dr. Purvi Parikh, an immunologist with the Allergy and Asthma Network, spoke to Cheddar about the ramifications of the authorization. "This is huge, especially because we know early treatment does keep people out of the hospital, especially with this antiviral," Parikh said. "The fact that people can start a regimen at home so they don't have to leave and further expose others is a big breakthrough." She also explained how the drug is a combination of two antiviral medications that are not without its risks but should be safe over the short term.
This year's worldwide semiconductor shortage limited the supply of everything from new cars to smartphones; and now, many in the chip industry expect the shortage to continue deep into 2022, and maybe even 2023. Semiconductor senior research analyst for Robert W. Baird & Co., Tristan Gerra, joins Cheddar News' Closing Bell to discuss.
Direct health care company Nomi Health recently raised $110 million in a Series A round. Nomi Health lets public and private organizations directly purchase healthcare at reduced costs, and pay providers in real-time. It also delivers healthcare directly to under-served communities via its fleet of mobile care units, which the company says is the largest in the country. Nomi Health says its mission is to improve the health care experience for all Americans. Nomi Health CEO Mark Newman joined Cheddar News' Closing Bell to discuss.
The airline industry says it is contending with staff shortages that threaten to hamper operations amid the COVID resurgence, andDelta Airlines CEO Ed Bastian called on the CDC to revise its guidance for vaccinated workers who test positive from a 10-day quarantine to just five. Chuck Liberman, chief investment officer and managing partner at Advisors Capital Management LLC, joined Cheddar to talk about the current guidance on isolation and why he believes the omicron variant calls for more relaxed guidance given its reportedly mild symptoms.
The boys discuss President Biden's plans to send out free rapid tests as the testing supply chain starts to buckle ahead of the holidays. Also, why aren't Americans having more babies, and The Matrix returns.
NASA is launching its new generation of space telescopes just before Christmas. The James Webb Space Telescope, set to launch on December 24th, will succeed the Hubble space telescope as the world's most powerful complex space observatory. The project has been 30 years in the making and is one of the most highly anticipated space science missions of the 21st century. Klaus Pontoppidan, astronomer and JWST Project Scientist at the Space Telescope Science Institute joined Cheddar's Opening Bell to discuss.
With Omicron becoming the dominant COVID-19 variant in the U.S., President Joe Biden announced that he will make 500 million rapid tests available to Americans in January 2022. Cheddar News speaks with Dr. Shereef Elnahal, President and CEO of University Hospital why testing is key to combatting the spread of the virus.
